Browse the evidence

Achieving optimal control of multiple risk factors (lifestyle and metabolic) in type 2 diabetes can restore life expectancy to levels comparable to individuals without diabetes.

If you have type 2 diabetes, focus on controlling your risk factors (blood sugar, blood pressure, lipids, smoking, diet, and exercise). Doing so can add 6-9 years to your life compared to poor management and may even bring your life expectancy in line with someone who doesn't have diabetes.

A healthy lifestyle can compensate for suboptimal metabolic control to provide longevity benefits in type 2 diabetes.

Even if your blood sugar or other metabolic numbers aren't perfect, maintaining a healthy lifestyle (not smoking, regular exercise, healthy diet) can still add 1.5-3.4 years to your life compared to someone who has perfect numbers but an unhealthy lifestyle.

Transitioning from obesity to non-obesity, transitioning from non-obesity to obesity, or maintaining stable obesity is associated with an elevated risk of chronic kidney disease (CKD) compared to maintaining stable non-obesity.

Maintaining a stable, non-obese weight is the most protective strategy for kidney health. Both gaining weight (if you are not obese) and losing weight (if you are obese) carry higher risks than staying stable. If you are obese, aim for gradual, sustainable weight management rather than rapid loss, as rapid loss may harm kidney function. Avoid weight cycling.

Extreme weight gain (≥20 kg) and substantial weight loss (>2.5 kg) are associated with increased CKD risk, forming a J-shaped or U-shaped relationship.

Avoid both extreme weight gain and substantial weight loss. Even small gains (≥2.5 kg) can increase kidney risk, especially in young adulthood. If you are obese, avoid rapid or substantial weight loss as it may also harm kidney function. Focus on stability.

The association between weight change patterns and CKD risk is stronger in individuals under 60 years of age at baseline compared to those 60 years or older.

If you are under 60, pay close attention to your weight stability. The risk to your kidneys from weight fluctuations is higher for you than for older adults. Prioritize maintaining a stable, healthy weight.

Exercise therapy reduces AHI and improves daytime sleepiness in OSA patients, often independently of significant weight loss, through mechanisms such as reduced leg fluid shift and improved upper airway neuromuscular control.

Incorporate 150 minutes of moderate aerobic exercise (like brisk walking) and resistance training twice a week into your routine. This can reduce the severity of your sleep apnea and improve daytime sleepiness, even if you don't lose a lot of weight. The benefits come from improved airway muscle control and reduced fluid shifts in your neck.

Baseline sleep disturbance significantly moderates the efficacy of behavioral weight loss interventions in breast cancer survivors, with poor sleepers achieving significantly less weight loss than better sleepers.

If you are a breast cancer survivor trying to lose weight, your sleep quality matters as much as your diet. If you have poor sleep, standard weight loss programs may be half as effective for you. Consider getting your sleep evaluated and treated before or during your weight loss journey to maximize results.

High adherence to the Mediterranean diet is characterized by a macronutrient profile with lower carbohydrate (46-49%) and higher protein (19-22%) and fat (31-33%) intake compared to standard recommendations, which is significantly associated with lower adiposity and inflammation.

If you follow a Mediterranean-style diet, focus on keeping carbohydrates on the lower end of the recommended range (around 46-49% of calories) while ensuring adequate protein (19-22%) and healthy fats (31-33%). This specific balance is linked to lower body fat and reduced inflammation compared to standard high-carb interpretations of the diet.

The mortality benefits of healthful plant-based diets are more pronounced in younger adults (<65 years) and men, while the risks of unhealthful plant-based diets are significantly stronger in individuals with obesity (BMI ≥ 25 kg/m²).

If you are under 65 or have obesity, paying close attention to the quality of your plant foods (choosing whole grains over refined ones) may offer you particularly strong protection against mortality. For older adults or those with normal BMI, the benefits still exist but may be less pronounced.

High consumption of ultra-processed foods (UPFs) is associated with higher total energy and macronutrient intake but lower micronutrient intake in Korean adults and older adults.

If you eat a lot of ultra-processed foods, you are likely consuming more total calories and macronutrients (carbs, protein, fat) while getting fewer essential micronutrients. Focus on identifying the major UPF contributors in your diet (like alcohol, grain products, or specific snacks) and consider replacing them with less processed alternatives to improve nutrient density without necessarily increasing total energy intake.

The primary sources of ultra-processed food energy intake vary by age group, with alcohol and grain-based products being major contributors across all groups, while legumes, milk, and dairy products become more significant contributors as UPF consumption increases and age rises.

Identify the specific ultra-processed foods that make up the bulk of your UPF intake. For many Koreans, this includes alcohol and grain-based products. For older adults, UPFs from legumes, milk, and dairy may also be significant contributors. Targeting these specific categories for reduction or substitution may be more effective than a blanket 'no UPF' rule.

Varying proximity-to-failure (progressively decreasing RIR from 4 to 1) does not enhance short-term muscle strength or hypertrophy compared to consistently training at 1 RIR in resistance-trained individuals.

If you are an experienced lifter, you do not need to vary your proximity to failure week-to-week to get stronger or bigger. Training consistently at 1 Repetition in Reserve (RIR 1) produces the same results as a program that starts easy (RIR 4) and gets harder (RIR 1). However, the varying approach results in lower perceived exertion (RPE) during the easier weeks, which may make the training feel less stressful without sacrificing gains.

Resistance-trained individuals have acceptable baseline accuracy in estimating Repetitions in Reserve (RIR), and this accuracy improves further when using a varying proximity-to-failure protocol (RIR 4-1).

If you are an experienced lifter, you can trust your ability to estimate how many reps you have left in the tank (RIR). You don't need to start from scratch. Using a training program that varies your intensity (starting easier and getting harder) can actually help you get better at estimating RIR, making your training more precise and effective.

Progressive increases in resistance training volume (weekly sets) linearly increase perceptual strain and monotony, but these perceptual metrics do not predict muscle hypertrophy (muscle thickness).

If you are increasing your weekly training sets, expect your perceived strain and monotony to go up. However, do not assume that this increased strain will lead to more muscle growth. The study found no link between how hard you perceive the training to be and actual muscle thickness gains. Focus on managing volume to avoid non-functional overreaching rather than chasing high strain as a proxy for hypertrophy.

Consuming an unprocessed diet reduces energy intake because participants preferentially select low-energy-dense components (fruits/vegetables) to meet micronutrient requirements, a behavior termed 'micronutrient deleveraging' that limits total caloric intake despite larger meal mass.

To manage energy intake without counting calories, prioritize unprocessed foods that are rich in micronutrients, such as fruits and vegetables. Your body may naturally limit your calorie intake if it prioritizes meeting its micronutrient needs, a process the authors call 'micronutrient deleveraging.' By choosing these foods, you may consume larger volumes of food with fewer calories, satisfying your nutritional requirements without overconsuming energy.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.

Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.

In patients with heart failure and reduced ejection fraction (HFrEF), a BMI greater than 27 kg/m² is associated with significantly higher risks of cardiovascular mortality, heart failure hospitalization, and composite adverse outcomes compared to a BMI of 24–27 kg/m².

If you have heart failure with reduced ejection fraction, maintaining a BMI between 24 and 27 kg/m² is associated with better survival and fewer hospitalizations than having a BMI over 27. This is especially true if your heart failure is caused by coronary artery disease (ischemic). You should discuss weight management strategies with your cardiologist, as higher BMI may increase your risk of cardiovascular death and hospitalization.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists significantly reduce major adverse cardiovascular events (MACE), with weight loss acting as the predominant mediator of this benefit compared to blood pressure reduction alone.

If you have type 2 diabetes or obesity and are at high cardiovascular risk, GLP-1RA medications can significantly lower your risk of heart attacks and strokes. The benefit comes largely from the weight loss these drugs cause, rather than just lowering blood pressure. Discuss these options with your doctor, especially if you have resistant hypertension.

Using ambulatory blood pressure monitoring (ABPM) instead of clinic-based measurements reveals a stronger and more consistent cardiovascular benefit from GLP-1RA therapy.

If you are on GLP-1RA therapy, ask your doctor about using ambulatory blood pressure monitoring (ABPM). It may provide a more accurate assessment of your cardiovascular risk and the effectiveness of your treatment compared to standard clinic blood pressure readings.

Incretin-based therapies (GLP-1RA and dual agonists) cause a mild absolute decrease in skeletal muscle mass and strength, but this is offset by a disproportionately larger loss of fat and liver mass, resulting in improved relative muscle-to-body-weight ratios and preserved or enhanced physical function.

If you are using incretin-based medications for weight loss, expect some loss of absolute muscle mass, but do not panic about 'wasting.' The medication preferentially burns fat and liver fat, which improves your muscle-to-weight ratio. Your strength and endurance often improve because you are carrying less weight. To maximize muscle retention, prioritize resistance training and adequate protein intake, as the drug itself does not protect muscle mass but does not disproportionately destroy it either.

Higher baseline insulin sensitivity is associated with greater retention of lean mass during diet-induced weight loss, but this protective effect is nullified when aerobic or resistance exercise is included in the intervention.

If you are losing weight through diet alone, your metabolic health (insulin sensitivity) dictates how much muscle you keep; those with better sensitivity lose less muscle. However, if you add exercise (especially resistance training), your baseline insulin sensitivity no longer matters for muscle preservation. Exercise protects muscle mass regardless of your metabolic profile, making it the most reliable tool for preserving lean mass during weight loss.

Orlistat, an anti-absorptive medication, produces modest weight loss (2.8-4.8% total body weight loss) by inhibiting gastric and pancreatic lipase.

Orlistat is an oral medication that works by blocking fat absorption, leading to modest weight loss (around 3-5%). It is less effective than newer injectable options and can cause gastrointestinal side effects like oily stools and urgency, which may limit its use.

Preobese individuals with a low relative resting metabolic rate (RMR) normalized for fat-free mass are at higher risk for future weight gain and obesity.

If you are preobese, your metabolic rate relative to your muscle mass might be lower than average, making you more prone to weight gain. Monitoring your metabolic rate or focusing on building fat-free mass could be beneficial strategies for prevention.